Analyzing Cost of Revenue: GSK plc and Amphastar Pharmaceuticals, Inc.

Analyzing Cost of Revenue: GSK plc vs. Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for GSK plc and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, GSK plc consistently reported a significantly higher cost of revenue, averaging around $9.9 billion annually, compared to Amphastar's $200 million. This stark contrast highlights GSK's expansive operations and market reach.

Key Insights

• GSK plc: Despite fluctuations, GSK's cost of revenue peaked in 2019 at approximately $11.9 billion, reflecting a 62% increase from 2014. However, a downward trend is observed post-2020, aligning with global economic shifts.
• Amphastar Pharmaceuticals, Inc.: Amphastar's cost of revenue grew steadily, with a notable 84% increase from 2014 to 2023, indicating strategic growth and market penetration.

These insights provide a window into the financial dynamics of two distinct pharmaceutical players, offering valuable perspectives for strategic decision-making.